Caseware UK (AP4) 2023.0.135 2023.0.135 false0The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2023-02-08falseNo description of principal activitytrue0true 14649747 2023-02-07 14649747 2023-02-08 2024-03-31 14649747 2022-04-01 2023-02-07 14649747 2024-03-31 14649747 c:Director2 2023-02-08 2024-03-31 14649747 c:Director5 2023-02-08 2024-03-31 14649747 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-03-31 14649747 d:CurrentFinancialInstruments 2024-03-31 14649747 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 14649747 d:ShareCapital 2024-03-31 14649747 d:RetainedEarningsAccumulatedLosses 2024-03-31 14649747 c:FRS102 2023-02-08 2024-03-31 14649747 c:AuditExempt-NoAccountantsReport 2023-02-08 2024-03-31 14649747 c:FullAccounts 2023-02-08 2024-03-31 14649747 c:PrivateLimitedCompanyLtd 2023-02-08 2024-03-31 14649747 d:EntityControlledByKeyManagementPersonnel1 2023-02-08 2024-03-31 14649747 d:EntityControlledByKeyManagementPersonnel1 2024-03-31 14649747 d:EntityControlledByKeyManagementPersonnel2 2023-02-08 2024-03-31 14649747 d:EntityControlledByKeyManagementPersonnel2 2024-03-31 14649747 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:InternallyGeneratedIntangibleAssets 2023-02-08 2024-03-31 14649747 e:PoundSterling 2023-02-08 2024-03-31 iso4217:GBP xbrli:pure
Company registration number: 14649747











BOURNE HEALTH LIMITED
Unaudited
Financial statements
Information for filing with the registrar
For the Period Ended 31 March 2024

















Coveney Nicholls Limited
Chartered Accountants
The Old Wheel House
31/37 Church Street
Reigate
Surrey
UK
RH2 0AD

 
BOURNE HEALTH LIMITED
Registered number:14649747

Statement of Financial Position
As at 31 March 2024

2024
Note
£

Fixed assets
  

Intangible assets
  
60,000

  
60,000

  

Creditors: amounts falling due within one year
 5 
(60,570)

Net current (liabilities)/assets
  
 
 
(60,570)

Total assets less current liabilities
  
(570)

  

Net (liabilities)/assets
  
(570)


Capital and reserves
  

Called up share capital 
  
150

Profit and loss account
  
(720)

  
(570)


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the Period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 7 November 2024.




___________________________
Syed Atif Hasan
___________________________
Qasim Hasani Syed
Director
Director

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
BOURNE HEALTH LIMITED
 
 
Notes to the Financial Statements

For the Period Ended 31 March 2024

1.


General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Purley War Memorial Hospital, 856, Brighton Road, Purley, Surrey, United Kingdom, CR8 2YL.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The directors consider the company to be a going concern. 
During the start up phase, whilst the product is being developed, the company will not generate any revenue, with losses expected initially. The directors therefore confirm their support and will ensure that any liabilities falling due will be met in order to enable the company to remain as a going concern for at least the next 12 months from the date of signing.

 
2.3

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.4

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

The company is currently in the process of developing an application which will allow patients to access medical advice. The project was started early 2023 and has since continued into the development phase in 2024. The product is expected to be brought to use in 2025 at which point the costs incured  in relation to the application development will begin to be amortised. 

Page 2

 
BOURNE HEALTH LIMITED
 
 
Notes to the Financial Statements

For the Period Ended 31 March 2024

2.Accounting policies (continued)

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees




The average monthly number of employees, including directors, during the Period was 0.


4.


Intangible assets



Development expenditure

£



Cost


Additions
60,000



At 31 March 2024

60,000






Net book value



At 31 March 2024
60,000




5.


Creditors: Amounts falling due within one year

2024
£

Trade creditors
59,850

Accruals and deferred income
720

60,570


Page 3

 
BOURNE HEALTH LIMITED
 
 
Notes to the Financial Statements

For the Period Ended 31 March 2024

6.


Related party transactions

The Bourne Partnership, which was controlled by Dr Q Syed, Dr A Hasan, Dr W Asher and Dr S Farhhan, all directors of the company, paid expenses during the year totalling £37,888 to fund the development costs of intangible assets. No interest is being charged on this amount. 
Portland Medical Centre, which was under the control of Dr R Tomar and Dr Y Rajbee, both directors of the company, paid expenses during the year of £21,962 to fund the development costs of intangible assets. No interest is being charged on this amount. 

 
Page 4